RNS Number : 7172Q
Beximco Pharmaceuticals Ltd
20 October 2023
 

 

20 October 2023

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

BEXIMCO PHARMACEUTICALS LIMITED

 

Notification of Preliminary Results and Annual General Meeting

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 19 October 2023. Please see further detail as follows:

 

 

1.

To recommend the approval of the Financial Statements for the year ended 30 June 2023

The Audited Financial Statements for the year ended 30 June 2023 have been approved. The full accounts are expected to be announced by 01 November 2023

2.

Date & Time of 47th Annual General Meeting ("AGM") of the Company for the year ended 30 June, 2023

28 December 2023 at 10.30 A.M.

3.

Venue of AGM

Virtual Platform

 

4.

Proposed Dividend for the year ended 30 June 2023

35% Cash Dividend (i.e. Tk 3.50 per Share)

5.

Record date

13 November 2023

 

 

Comparative Financial Disclosures:

 

Beximco Pharmaceuticals Limited (Stand-alone)

 

 

Particulars

Year ended

30 June 2023

Year ended

30 June 2022

Net Profit after Tax

Tk. 4,588,008,908

Tk.  5,161,343,643

Earnings Per Share (EPS)

Tk. 10.28

Tk. 11.57

Net Asset Value (NAV)

Tk. 43,341,239,142

Tk. 40,315,738,301

Net Asset Value per share (NAVPS)

Tk.97.15

Tk. 90.37

Net Operating Cash Flow Per Share (NOCFPS)

Tk. 12.96

Tk. 11.27

 

 

Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)

 

Particulars

Year ended

30 June 2023

Year ended

30 June 2022

Net Profit after Tax

Tk. 4,524,468,490

Tk. 4,998,628,197

Earnings Per Share (EPS)

Tk. 10.34

Tk. 11.48

Net Asset Value (NAV)

Tk. 43,680,703,738

Tk. 40,600,497,817

Net Asset Value per share (NAVPS)

Tk. 97.91

Tk. 91.01

Net Operating Cash Flow Per Share (NOCFPS)

Tk. 13.64

Tk. 11.69

 

 

 

For further information please visit www.beximcopharma.com or enquire to:

 

Beximco Pharma

 

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, Ext.20080

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

 

Beximco Pharma?s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORGPGAWUUPWGCB